<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03231033</url>
  </required_header>
  <id_info>
    <org_study_id>TPSC-114</org_study_id>
    <nct_id>NCT03231033</nct_id>
  </id_info>
  <brief_title>Pioglitazone Therapy of Autoimmune Pulmonary Alveolar Proteinosis Autoimmune Pulmonary Alveolar Proteinosis</brief_title>
  <acronym>PioPAP</acronym>
  <official_title>First in Human Study of Pioglitazone Therapy of Autoimmune Pulmonary Alveolar Proteinosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital Medical Center, Cincinnati</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pulmonary alveolar proteinosis (PAP) is a syndrome of surfactant accumulation, respiratory&#xD;
      failure, and innate immune deficiency for which therapy remains limited to whole lung lavage&#xD;
      (WLL), an invasive physical procedure to remove surfactant unavailable at most medical&#xD;
      centers. While PAP occurs in multiple diseases affecting men, women, and children of all ages&#xD;
      and ethnic origins, in 85% of patients, it occurs as an idiopathic disease associated with&#xD;
      neutralizing GM-CSF autoantibodies. Basic science and translational research has shown that&#xD;
      idiopathic PAP is an autoimmune disease in which disruption of GM-CSF signaling impairs the&#xD;
      ability of alveolar macrophages to clear surfactant and perform host defense functions.&#xD;
&#xD;
      Recently, it has been shown that cholesterol toxicity drives pathogenesis in alveolar&#xD;
      macrophages from GM-CSF deficient (Csf2-/-) mice and patients with autoimmune PAP. Loss of&#xD;
      GM-CSF signaling reduces PU.1/CEBP-mediated expression of PPARγ and its downstream target&#xD;
      ABCG1 (a cholesterol exporter important in macrophages). The cell responds by esterifying and&#xD;
      storing cholesterol in vesicles to reduce toxicity. Eventually, vesicles fill the cell,&#xD;
      impair intracellular transport and reduce uptake and clearance of surfactant from the lung&#xD;
      surface resulting in disease manifestations. Recent data indicates that pioglitazone, a PPARγ&#xD;
      agonist currently approved by the FDA for human use, increases cholesterol/surfactant&#xD;
      clearance by alveolar macrophages from autoimmune PAP patients and Csf2-/- mice. Importantly,&#xD;
      pioglitazone significantly reduced the severity of PAP lung disease in Csf2-/- mice after&#xD;
      several months of therapy. Together, these observations suggest pioglitazone could be&#xD;
      'repurposed' as pharmacologic therapy for PAP.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PAP is a rare syndrome of surfactant accumulation and resulting hypoxemic respiratory failure&#xD;
      that occurs in multiple diseases that can be classified on the basis of pathogenesis into&#xD;
      three groups: primary PAP (caused by disruption of GM-CSF signaling - autoimmune PAP,&#xD;
      hereditary PAP), secondary PAP (caused by reduction in alveolar macrophage numbers and/or&#xD;
      functions), and metabolic disorders of surfactant production-related PAP (caused by mutations&#xD;
      in genes required for normal surfactant production). Blood tests are capable of identifying&#xD;
      the PAP-causing disease in about 95% of patients.&#xD;
&#xD;
      Research has demonstrated that aPAP is caused by a high level of GM-CSF autoantibodies, which&#xD;
      block GM-CSF signaling. Normally, alveolar macrophages clear (remove) about half of the used&#xD;
      surfactant from air sacs (alveoli) in the lungs. Without GM-CSF, alveolar macrophages have a&#xD;
      reduced ability to clear surfactant, which builds up in the alveoli and the blocks delivery&#xD;
      of oxygen into the blood, resulting in a low blood oxygen level and a reduced oxygen delivery&#xD;
      to tissues of the body. This macrophage defect is thought to occur because loss of GM-CSF&#xD;
      stimulation causes reduced activity of PPAR-gamma, a molecule present within alveolar&#xD;
      macrophages that they require to simulate the ability to clear surfactant: the reduction in&#xD;
      PPAR-gamma activity cause a functional impairment of surfactant clearance by alveolar&#xD;
      macrophages.&#xD;
&#xD;
      Currently, no pharmacologic agent has been FDA-approved as therapy aPAP: it is currently&#xD;
      treated by whole lung lavage, a procedure requiring general anesthesia and a breathing&#xD;
      machine the lungs are individually filled with saline and drained repeatedly to physically&#xD;
      remove the excess surfactant. Recent research has shown that pioglitazone, a drug that&#xD;
      activates PPAR-gamma, is able to increase the ability of cultured macrophages to clear&#xD;
      surfactant in the laboratory and that oral administration is able to reduce lung disease&#xD;
      severity and be well-tolerated in a mouse model of aPAP. Currently, pioglitazone is approved&#xD;
      by the FDA for treatment of increased blood sugar in patients with diabetes.&#xD;
&#xD;
      This study is a pilot phase I/II human clinical trial of oral pioglitazone as therapy for&#xD;
      autoimmune PAP. The target population is adults with aPAP who have measurable, clinically&#xD;
      significant disease satisfying all of the inclusion and exclusion criteria. The study design&#xD;
      will involve recruitment, screening, and enrollment of participants into a phase I,&#xD;
      open-label, dose-escalating, single site study. Oral pioglitazone will be administered to&#xD;
      autoimmune PAP patients with a personalized dose escalation plan beginning at 15 mg per day,&#xD;
      advancing to 30 mg per day and then 45 mg per day, if tolerated, in 12 week increments.&#xD;
      Adverse events (AEs), serious AEs (SAEs), and pharmacodynamics (PD) parameters will be&#xD;
      evaluated. The experimental approach will evaluate 1) safety of oral pioglitazone by&#xD;
      documenting occurrence of treatment-emergent AEs and SAEs, 2) physiological effects of oral&#xD;
      pioglitazone by measuring changes in the physiological, clinical, and quality of life&#xD;
      parameters and 3) biochemical effects of pioglitazone on the transcriptome, phenotype, and&#xD;
      function of mononuclear phagocytes (alveolar macrophages and monocytes) from autoimmune PAP&#xD;
      patients. Anticipated results will determine the safety, efficacy, and biochemical effects of&#xD;
      oral pioglitazone in patients with autoimmune PAP. These results will impact the field by 1)&#xD;
      monitoring safety of oral pioglitazone in autoimmune PAP patients, 2) translating existing&#xD;
      preclinical data in humans, and 3) demonstrating the results of pioglitazone in a&#xD;
      personalized treatment plan with dose escalation in a pilot trial to evaluate the efficacy of&#xD;
      oral pioglitazone for aPAP.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 17, 2017</start_date>
  <completion_date type="Actual">April 2, 2019</completion_date>
  <primary_completion_date type="Actual">April 2, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of any treatment-emergent adverse events and serious adverse events</measure>
    <time_frame>1 year</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Alveolar-arterial oxygen concentration gradient (A-aDO2)</measure>
    <time_frame>1 year</time_frame>
    <description>Change from Baseline (Day 0) in the A-aDO2 gradient as measured at the End of Treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PaO2</measure>
    <time_frame>1 year</time_frame>
    <description>Change from Baseline (Day 0) in the PaO2 as measured at the End of Treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum SpO2 during a standardized treadmill exercise test</measure>
    <time_frame>1 year</time_frame>
    <description>Change from Baseline (Day 0) in the minimum SpO2 during a treadmill exercise test as measured at the End of Treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time during a standardized treadmill exercise test required for SpO2 to fall below 88% (or discontinuance of testing due to dyspnea)</measure>
    <time_frame>1 year</time_frame>
    <description>Change from Baseline (Day 0) in the time for the SpO2 to fall below 88% during the treadmill exercise test as measured at the End of Treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DLCO (Diffusion capacity of the lung for carbon monoxide)</measure>
    <time_frame>1 year</time_frame>
    <description>Change from Baseline (Day 0) in the DLCO as measured at the End of Treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parenchymal lung density determined by quantitative computed tomography (CT) densitometry</measure>
    <time_frame>1 year</time_frame>
    <description>Change from Baseline (Day 0) in the parenchymal densitometry as measured at the End of Treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life measured by SF-36</measure>
    <time_frame>1 year</time_frame>
    <description>Change from Baseline (Day 0) in the quality of life as measured at the End of Treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life measured by St. George's Respiratory Questionnaire</measure>
    <time_frame>1 year</time_frame>
    <description>Change from Baseline (Day 0) in the quality of life as measured at the End of Treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Shortness of breath measured by San Diego Dyspnea Score</measure>
    <time_frame>1 year</time_frame>
    <description>Change from Baseline (Day 0) in the quality of life as measured at the End of Treatment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Autoimmune Pulmonary Alveolar Proteinosis</condition>
  <arm_group>
    <arm_group_label>Pioglitazone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration of Actos at 15 mg/day for 12 weeks, 30 mg/day for 12 weeks, and 45 mg/day for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone</intervention_name>
    <description>Participants will receive three doses of Pioglitazone, 15 mg/day for 12 weeks, 30 mg/day for 12 weeks, and 45 mg/day for 12 weeks</description>
    <arm_group_label>Pioglitazone</arm_group_label>
    <other_name>Actos</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female&#xD;
&#xD;
          -  Age ≥ 18 years and ≤ 80 years&#xD;
&#xD;
          -  Able to understand and willing to sign a written informed consent document&#xD;
&#xD;
          -  Able and willing to complete administration of study drug at home&#xD;
&#xD;
          -  Able and willing to adhere to study visit schedule and study procedures&#xD;
&#xD;
          -  Diagnosis of aPAP determined by:&#xD;
&#xD;
               -  History of a diagnosis of PAP with or without supporting lung histology or&#xD;
                  BAL/cytology and&#xD;
&#xD;
               -  Abnormal serum GM-CSF autoantibody test (GMAb ELISA Test) and&#xD;
&#xD;
               -  Chest CT findings compatible with a diagnosis of aPAP&#xD;
&#xD;
          -  Evidence of impaired GM-CSF signaling demonstrated by an abnormal STAT5&#xD;
             phosphorylation index (STAT5-PI) test measured in heparinized whole blood at the time&#xD;
             screening&#xD;
&#xD;
          -  A-aDO2 ≥ 25 mm Hg&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of any other PAP-causing disease&#xD;
&#xD;
          -  aPAP complicated by:&#xD;
&#xD;
               -  Severe disease at screening/enrollment (A-aD02&lt;55)&#xD;
&#xD;
               -  Clinically significant pulmonary fibrosis&#xD;
&#xD;
          -  History of any clinically significant:&#xD;
&#xD;
               -  Other lung disease&#xD;
&#xD;
               -  Cardiovascular disease&#xD;
&#xD;
               -  Disease requiring use of systemic steroids in past year&#xD;
&#xD;
               -  History of Diabetes Mellitus&#xD;
&#xD;
               -  History of untreated osteoporosis&#xD;
&#xD;
               -  History of bladder cancer&#xD;
&#xD;
               -  Active / serious lung or systemic infection&#xD;
&#xD;
               -  Persistent or unexplained fever &gt;101oF within 2 months of study&#xD;
&#xD;
               -  Treatment with an investigational therapeutic agent for aPAP within 3 months&#xD;
                  prior to enrollment, which includes inhaled GM-CSF&#xD;
&#xD;
               -  Abnormal clinical and/or laboratory parameters at screening&#xD;
&#xD;
               -  Women who are pregnant or plan to become pregnant&#xD;
&#xD;
               -  Concomitant or recent use of specific medicines&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruce Trapnell, MD</last_name>
    <role>Study Director</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>June 19, 2017</study_first_submitted>
  <study_first_submitted_qc>July 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2017</study_first_posted>
  <last_update_submitted>January 15, 2020</last_update_submitted>
  <last_update_submitted_qc>January 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Alveolar Proteinosis</mesh_term>
    <mesh_term>Autoimmune Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03231033
org study id: TPSC-114
nct id: NCT03231033
lead sponsor: 
has dmc: Yes
is fda regulated drug: Yes
is fda regulated device: No
is us export: No
Pulmonary alveolar proteinosis (PAP) is a syndrome of surfactant accumulation, respiratory
      failure, and innate immune deficiency for which therapy remains limited to whole lung lavage
      (WLL), an invasive physical procedure to remove surfactant unavailable at most medical
      centers. While PAP occurs in multiple diseases affecting men, women, and children of all ages
      and ethnic origins, in 85% of patients, it occurs as an idiopathic disease associated with
      neutralizing GM-CSF autoantibodies. Basic science and translational research has shown that
      idiopathic PAP is an autoimmune disease in which disruption of GM-CSF signaling impairs the
      ability of alveolar macrophages to clear surfactant and perform host defense functions.

      Recently, it has been shown that cholesterol toxicity drives pathogenesis in alveolar
      macrophages from GM-CSF deficient (Csf2-/-) mice and patients with autoimmune PAP. Loss of
      GM-CSF signaling reduces PU.1/CEBP-mediated expression of PPARγ and its downstream target
      ABCG1 (a cholesterol exporter important in macrophages). The cell responds by esterifying and
      storing cholesterol in vesicles to reduce toxicity. Eventually, vesicles fill the cell,
      impair intracellular transport and reduce uptake and clearance of surfactant from the lung
      surface resulting in disease manifestations. Recent data indicates that pioglitazone, a PPARγ
      agonist currently approved by the FDA for human use, increases cholesterol/surfactant
      clearance by alveolar macrophages from autoimmune PAP patients and Csf2-/- mice. Importantly,
      pioglitazone significantly reduced the severity of PAP lung disease in Csf2-/- mice after
      several months of therapy. Together, these observations suggest pioglitazone could be
      'repurposed' as pharmacologic therapy for PAP.
PAP is a rare syndrome of surfactant accumulation and resulting hypoxemic respiratory failure
      that occurs in multiple diseases that can be classified on the basis of pathogenesis into
      three groups: primary PAP (caused by disruption of GM-CSF signaling - autoimmune PAP,
      hereditary PAP), secondary PAP (caused by reduction in alveolar macrophage numbers and/or
      functions), and metabolic disorders of surfactant production-related PAP (caused by mutations
      in genes required for normal surfactant production). Blood tests are capable of identifying
      the PAP-causing disease in about 95% of patients.

      Research has demonstrated that aPAP is caused by a high level of GM-CSF autoantibodies, which
      block GM-CSF signaling. Normally, alveolar macrophages clear (remove) about half of the used
      surfactant from air sacs (alveoli) in the lungs. Without GM-CSF, alveolar macrophages have a
      reduced ability to clear surfactant, which builds up in the alveoli and the blocks delivery
      of oxygen into the blood, resulting in a low blood oxygen level and a reduced oxygen delivery
      to tissues of the body. This macrophage defect is thought to occur because loss of GM-CSF
      stimulation causes reduced activity of PPAR-gamma, a molecule present within alveolar
      macrophages that they require to simulate the ability to clear surfactant: the reduction in
      PPAR-gamma activity cause a functional impairment of surfactant clearance by alveolar
      macrophages.

      Currently, no pharmacologic agent has been FDA-approved as therapy aPAP: it is currently
      treated by whole lung lavage, a procedure requiring general anesthesia and a breathing
      machine the lungs are individually filled with saline and drained repeatedly to physically
      remove the excess surfactant. Recent research has shown that pioglitazone, a drug that
      activates PPAR-gamma, is able to increase the ability of cultured macrophages to clear
      surfactant in the laboratory and that oral administration is able to reduce lung disease
      severity and be well-tolerated in a mouse model of aPAP. Currently, pioglitazone is approved
      by the FDA for treatment of increased blood sugar in patients with diabetes.

      This study is a pilot phase I/II human clinical trial of oral pioglitazone as therapy for
      autoimmune PAP. The target population is adults with aPAP who have measurable, clinically
      significant disease satisfying all of the inclusion and exclusion criteria. The study design
      will involve recruitment, screening, and enrollment of participants into a phase I,
      open-label, dose-escalating, single site study. Oral pioglitazone will be administered to
      autoimmune PAP patients with a personalized dose escalation plan beginning at 15 mg per day,
      advancing to 30 mg per day and then 45 mg per day, if tolerated, in 12 week increments.
      Adverse events (AEs), serious AEs (SAEs), and pharmacodynamics (PD) parameters will be
      evaluated. The experimental approach will evaluate 1) safety of oral pioglitazone by
      documenting occurrence of treatment-emergent AEs and SAEs, 2) physiological effects of oral
      pioglitazone by measuring changes in the physiological, clinical, and quality of life
      parameters and 3) biochemical effects of pioglitazone on the transcriptome, phenotype, and
      function of mononuclear phagocytes (alveolar macrophages and monocytes) from autoimmune PAP
      patients. Anticipated results will determine the safety, efficacy, and biochemical effects of
      oral pioglitazone in patients with autoimmune PAP. These results will impact the field by 1)
      monitoring safety of oral pioglitazone in autoimmune PAP patients, 2) translating existing
      preclinical data in humans, and 3) demonstrating the results of pioglitazone in a
      personalized treatment plan with dose escalation in a pilot trial to evaluate the efficacy of
      oral pioglitazone for aPAP.
allocation: N/A
intervention model: Single Group Assignment
primary purpose: Basic Science
masking: None (Open Label)
measure: Occurrence of any treatment-emergent adverse events and serious adverse events
time frame: 1 year
description: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
measure: Alveolar-arterial oxygen concentration gradient (A-aDO2)
time frame: 1 year
description: Change from Baseline (Day 0) in the A-aDO2 gradient as measured at the End of Treatment
measure: PaO2
time frame: 1 year
description: Change from Baseline (Day 0) in the PaO2 as measured at the End of Treatment
measure: Minimum SpO2 during a standardized treadmill exercise test
time frame: 1 year
description: Change from Baseline (Day 0) in the minimum SpO2 during a treadmill exercise test as measured at the End of Treatment
measure: Time during a standardized treadmill exercise test required for SpO2 to fall below 88% (or discontinuance of testing due to dyspnea)
time frame: 1 year
description: Change from Baseline (Day 0) in the time for the SpO2 to fall below 88% during the treadmill exercise test as measured at the End of Treatment
measure: DLCO (Diffusion capacity of the lung for carbon monoxide)
time frame: 1 year
description: Change from Baseline (Day 0) in the DLCO as measured at the End of Treatment
measure: Parenchymal lung density determined by quantitative computed tomography (CT) densitometry
time frame: 1 year
description: Change from Baseline (Day 0) in the parenchymal densitometry as measured at the End of Treatment
measure: Quality of Life measured by SF-36
time frame: 1 year
description: Change from Baseline (Day 0) in the quality of life as measured at the End of Treatment
measure: Quality of Life measured by St. George's Respiratory Questionnaire
time frame: 1 year
description: Change from Baseline (Day 0) in the quality of life as measured at the End of Treatment
measure: Shortness of breath measured by San Diego Dyspnea Score
time frame: 1 year
description: Change from Baseline (Day 0) in the quality of life as measured at the End of Treatment
arm group label: Pioglitazone
arm group type: Experimental
description: Oral administration of Actos at 15 mg/day for 12 weeks, 30 mg/day for 12 weeks, and 45 mg/day for 12 weeks
intervention type: Drug
intervention name: Pioglitazone
description: Participants will receive three doses of Pioglitazone, 15 mg/day for 12 weeks, 30 mg/day for 12 weeks, and 45 mg/day for 12 weeks
arm group label: Pioglitazone
other name: Actos
criteria: 
gender: All
minimum age: 18 Years
maximum age: 80 Years
healthy volunteers: No
last name: Bruce Trapnell, MD
role: Study Director
affiliation: Children's Hospital Medical Center, Cincinnati
facility: 
country: United States
responsible party type: Sponsor
mesh term: Pulmonary Alveolar Proteinosis
mesh term: Autoimmune Diseases
mesh term: Pioglitazone